$Summit Therapeutics(SMMT)$
summit很有信心，声称也要努力推进单药治疗的应用
The second question around HARMONi-2 and HARMONi-3, remember, HARMONi-2 is a China-only study. And I think we want to be clear that it was never anticipated that we would be able to file on the HARMONi-2 data. However, given the strength of the data, we're going to sort of make every way possible to make this therapy available to patients as soon as possible.
In addition, the question around PFS translating to OS, I would say that for HARMONi-2 and HARMONi-3, the earlier study usually occurs in other words, the earlier you make therapy available for patients, the more likely that you'll have a translation for PFS to OS. There's always the risk that PFS won't translate to OS. But again, given the strength of the data and the trends that we're observing gives us very good confidence that we'll hit those end points. Go ahead, Jack.
全部讨论
$康方生物(09926)$ 夏姐姐没说的话，summit说了
Summit的问答里干货很多啊，咋没人转载呢
Answer
Howard (Jack) West (Executives)
If I can add anything, this is Jack. For me, I think it was extremely important that the press release specifies that the PFS improvement was observed broadly across the different subgroups that included the low and the high as well as adeno and squamous. And we've seen extremely promising results in squamous and this really showed us it is not limited to any one group kind of pulling anybody else across the goal line, but rather that this is really seen everywhere.
I'd also note that, of course, pembrolizumab was the first of these agents that was approved in first-line non-small cell lung cancer back in 2016 that changed everything and it has been the pacesetter with great results in high PD-L1. That was back in 2016. The first of them, that's been a high bar and showing that you can beat pembrolizumab in a setting where it has achieved very well is a very strong statement. So it's not just winning in the setting where there might be some relative weakness, but winning across the board and even in an area where pembrolizumab has been known to be an extremely strong treatment, and you can hope to do better than that is a real statement, I would say.
But again, given the strength of the data and the trends that we're observing gives us very good confidence that we'll hit those end points. Go ahead, Jack.
现在数据的强度和趋势给我们极大的信心将来会胜出。
关于HARMONi-2和HARMONi-3的第二个问题，请注意，HARMONi-2仅在中国进行。我认为我们需要明确，我们从未预期能够基于HARMONi-2的数据提交申请。然而，鉴于数据的强度，我们将尽一切可能使这种疗法尽快可供患者使用。
此外，关于PFS转化为OS的问题，我想说对于HARMONi-2和HARMONi-3，早期的研究通常在其他方面发生，换句话说，你越早为患者提供治疗，PFS转化为OS的可能性就越大。但总是存在PFS不会转化为OS的风险。但是，再次强调，鉴于数据的强度和我们观察到的趋势，我们非常有信心达到这些终点。继续吧，Jack。